{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:51:51Z","timestamp":1784274711094,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Adenoid cystic carcinoma (ACC) is a rare cancer that arises from the salivary glands. Recent studies have shown that prostate-specific membrane antigen (PSMA) expression is high in ACC. We conducted a prospective study to evaluate clinical factors associated with high [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 uptake and to report preliminary therapeutic outcomes of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA therapy in recurred or metastatic ACC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Thirty patients were prospectively enrolled. Any focal accumulation of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 not explained by physiological uptake was defined as pathological lesions. Clinicopathological features relevant for high [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 uptake in recurred or metastatic ACC were analyzed. Therapeutic outcomes of patients who received\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA therapy under compassionate use were also reviewed as a secondary component.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 238 lesions were evaluated, and the SUV\n                      <jats:sub>max<\/jats:sub>\n                      ranged between 0.9 and 11.0, showing mild to moderate PSMA uptake. Higher SUV\n                      <jats:sub>max<\/jats:sub>\n                      was observed in lung and bone metastases. The longest tumor diameter (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.190,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009) and tumor % growth rate (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.220,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006) were significantly correlated with SUV\n                      <jats:sub>max<\/jats:sub>\n                      . A longer duration from diagnosis was a relevant factor for high [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 uptake. Seven patients received\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA therapy, but therapeutic outcomes were limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      High [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 uptake in recurred or metastatic ACC was associated with location of metastases, longer tumor diameter, high tumor % growth rate, and a longer duration from diagnosis. While\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA therapy was performed in a limited cohort and outcomes were preliminary, these findings provide exploratory insights into potential factors relevant for patient selection and warrant further investigation in larger studies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13139-025-00955-9","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:18:12Z","timestamp":1761189492000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Characteristics Associated with High [68Ga]Ga-PSMA-11 Uptake and Preliminary Therapeutic Outcomes in Patients with Metastatic Adenoid Cystic Carcinoma"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3576-9899","authenticated-orcid":false,"given":"Hyunpil","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-8552","authenticated-orcid":false,"given":"Minseok","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-9945","authenticated-orcid":false,"given":"Joonhyung","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-5186","authenticated-orcid":false,"given":"Gi Jeong","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-9017","authenticated-orcid":false,"given":"Keon Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"955_CR1","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1002\/cncr.27408","volume":"118","author":"CL Ellington","year":"2012","unstructured":"Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973\u20132007 surveillance, epidemiology, and end results data. Cancer. 2012;118:4444\u201351.","journal-title":"Cancer"},{"key":"955_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105213","volume":"115","author":"L Lorini","year":"2021","unstructured":"Lorini L, Ardighieri L, Bozzola A, Romani C, Bignotti E, Buglione M, et al. Prognosis and management of recurrent and\/or metastatic head and neck adenoid cystic carcinoma. Oral Oncol. 2021;115:105213.","journal-title":"Oral Oncol"},{"key":"955_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","volume":"12","author":"SA Laurie","year":"2011","unstructured":"Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12:815\u201324.","journal-title":"Lancet Oncol"},{"key":"955_CR4","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","volume":"27","author":"EJ Kang","year":"2021","unstructured":"Kang EJ, Ahn MJ, Ock CY, Lee KW, Kwon JH, Yang Y, et al. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2021;27:5272\u20139.","journal-title":"Clin Cancer Res"},{"key":"955_CR5","doi-asserted-by":"publisher","unstructured":"Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061367.","DOI":"10.3390\/cancers12061367"},{"key":"955_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"955_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s13139-016-0445-6","volume":"51","author":"B de Keizer","year":"2017","unstructured":"de Keizer B, Krijger GC, Ververs FT, van Es RJJ, de Bree R, Willems S. (68)Ga-PSMA PET-CT imaging of metastatic adenoid cystic carcinoma. Nucl Med Mol Imaging. 2017;51:360\u20131.","journal-title":"Nucl Med Mol Imaging"},{"key":"955_CR8","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s00259-017-3737-x","volume":"44","author":"TJW Klein Nulent","year":"2017","unstructured":"Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging. 2017;44:1614\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"955_CR9","first-page":"79","volume":"7","author":"L Konig","year":"2017","unstructured":"Konig L, Hauswald H, Flechtenmacher C, Heller M, Debus J, Haberkorn U, et al. Uptake of prostate-specific membrane antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology? Clin Transl Radiat Oncol. 2017;7:79\u201382.","journal-title":"Clin Transl Radiat Oncol"},{"key":"955_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/RLU.0000000000001220","volume":"41","author":"S Lutje","year":"2016","unstructured":"Lutje S, Sauerwein W, Lauenstein T, Bockisch A, Poeppel TD. In vivo visualization of Prostate-Specific membrane antigen in adenoid cystic carcinoma of the salivary gland. Clin Nucl Med. 2016;41:476\u20137.","journal-title":"Clin Nucl Med"},{"key":"955_CR11","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.7150\/thno.38501","volume":"10","author":"W van Boxtel","year":"2020","unstructured":"van Boxtel W, Lutje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, et al. (68)Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;10:2273\u201383.","journal-title":"Theranostics"},{"key":"955_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06847-9","volume":"20","author":"TJW Klein Nulent","year":"2020","unstructured":"Klein Nulent TJW, Valstar MH, Smit LA, Smeele LE, Zuithoff NPA, de Keizer B, et al. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer. 2020;20:519.","journal-title":"BMC Cancer"},{"issue":"6","key":"955_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13139-022-00764-4","volume":"56","author":"SW Oh","year":"2022","unstructured":"Oh SW, Suh M, Cheon GJ. Current status of PSMA-targeted radioligand therapy in the era of radiopharmaceutical therapy acquiring marketing authorization. Nucl Med Mol Imaging. 2022;56(6):263\u201381.","journal-title":"Nucl Med Mol Imaging"},{"key":"955_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.120.246983","volume":"62","author":"S Harsini","year":"2021","unstructured":"Harsini S, Saprunoff H, Alden T, Mohammadi B, Wilson D, Benard F. The effects of monosodium glutamate on PSMA Radiotracer uptake in men with recurrent prostate cancer: A prospective, randomized, Double-Blind, Placebo-Controlled intraindividual imaging study. J Nucl Med. 2021;62:81\u20137.","journal-title":"J Nucl Med"},{"key":"955_CR15","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2967\/jnumed.118.215350","volume":"59","author":"E Rousseau","year":"2018","unstructured":"Rousseau E, Lau J, Kuo HT, Zhang Z, Merkens H, Hundal-Jabal N, et al. Monosodium glutamate reduces (68)Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate cancer model. J Nucl Med. 2018;59:1865\u20138.","journal-title":"J Nucl Med"},{"key":"955_CR16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","volume":"60","author":"NJ Rupp","year":"2019","unstructured":"Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Topfer A, Muller J, et al. First clinicopathologic evidence of a non-PSMA-related uptake mechanism for (68)Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60:1270\u20136.","journal-title":"J Nucl Med"},{"key":"955_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"955_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"955_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"955_CR20","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert R, Seitzer K, Herrmann K, Kessel K, Schafers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812\u201320.","journal-title":"Theranostics"},{"key":"955_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13550-021-00866-8","volume":"11","author":"TJW Klein Nulent","year":"2021","unstructured":"Klein Nulent TJW, van Es RJJ, Willems SM, Braat A, Devriese LA, de Bree R, et al. First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021;11:126.","journal-title":"EJNMMI Res"},{"issue":"14","key":"955_CR22","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.7150\/thno.99035","volume":"14","author":"NJ van Ruitenbeek","year":"2024","unstructured":"van Ruitenbeek NJ, Uijen MJM, Driessen CML, Peters SMB, Prive BM, van Engen-van Grunsven ACH, et al. Luthetisum-177-PSMA therapy for recurrent\/metastatic salivary gland cancer: a prospective pilot study. Theranostics. 2024;14(14):5388\u201399.","journal-title":"Theranostics"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-025-00955-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:27:36Z","timestamp":1770449256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-025-00955-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1007\/s13139-025-00955-9","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI, May 2023 version)to check grammar and enhance readability. After using this tool, the authors carefully reviewed and edited the content as necessary and take full responsibility for the final content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}},{"value":"This study was approved by Institutional Review Board of Seoul National Universitiy Hospital (approval no. H-2110-097-1263, H-2022-015-1297). All individual participants provided a written informed consent. All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and the Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The Institutional Review Board of Seoul National Universitiy Hospital approved this study, and the requirement to obtain informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Gi Jeong Cheon served as an editorial board member of Nuclear Medicine and Molecular Imaging during the conduct of this study. The role did not influence the review or editorial decision-making process. Hyunpil Sung, Minseok Suh, Joonhyung Gil, Bhumsuk Keam, and Keon Wook Kang declare no conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}